Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. (Nasdaq: SEER) is a life sciences company focused on deep, unbiased proteomics, and the SEER news feed reflects that focus. Company press releases highlight how Seer’s Proteograph Product Suite—combining proprietary engineered nanoparticles, automation instrumentation, consumables, and analytical software—is being used in large-scale and translational research across cardiovascular disease, oncology, aging biology, and other areas of human health.
Investors and researchers following SEER news will find regular updates on financial results, platform launches, and scientific validation. Seer’s quarterly earnings announcements describe revenue from Proteograph instruments, consumable kits, and Technology Access Center service projects, along with commentary on adoption of its platform and the growth of third-party publications and preprints that use its technology.
The news stream also covers Seer’s presence at major scientific and investor conferences. Releases detail presentations at meetings such as the Human Proteome Organization World Congress and the American Society of Human Genetics, where independent and collaborative studies showcase applications of the Proteograph platform in deep plasma proteomics, biomarker discovery, proteogenomics, and multi-omic precision medicine research. Other items include participation in healthcare and life sciences investor conferences, as well as board and governance updates.
For those tracking how proteomics technologies are being deployed in population-scale and translational studies, Seer’s news provides insight into collaborations, such as population-scale proteomics projects and genome-wide association studies using the Proteograph platform. Bookmarking the SEER news page offers a centralized view of Seer’s financial disclosures, scientific milestones, and corporate developments as reported in its official communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Seer, Inc. (Nasdaq: SEER), a life sciences company specializing in proteomics, will release its financial results for Q1 2023 after market close on May 9, 2023. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET, accessible via the Investor section of their website. Seer’s Proteograph™ Product Suite offers a breakthrough solution for unbiased proteomic analysis, streamlining laboratory workflows with engineered nanoparticles, consumables, automation, and software. Designed for research applications only, the Proteograph enables deep analysis in hours, enhancing lab efficiency.
Seer Inc. (NASDAQ: SEER) announced a study in PLOS One revealing new protein variants associated with non-small cell lung cancer (NSCLC) using the Proteograph Product Suite. Collaborating with Memorial Sloan Kettering Cancer Center, researchers identified four protein isoforms linked to NSCLC progression, highlighting their potential as new biomarkers. Notably, the short protein isoform of BMP1 was found more frequently in late-stage NSCLC patients. The analysis included 188 plasma samples from NSCLC patients and controls. Results underscore the importance of unbiased proteomics for advancing cancer research and diagnosis.
Seer Inc. (Nasdaq: SEER) reported a significant revenue increase of 134% in 2022, reaching $15.5 million, with fourth-quarter revenue of $4.6 million, a 50% year-over-year rise. Instruments shipped rose 129% with a total of 39 units by year-end. Despite growth, the company faced a net loss of $93.0 million for the year. Operating expenses surged to $104.3 million
, leading to a gross profit margin of 46%. For 2023, Seer forecasts revenue between $23 million and $25 million, indicating a growth rate of 48% to 61%.
Seer, a life sciences company specializing in proteomics, announced participation in the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 8, 2023. The company’s management will engage in a fireside chat and Q&A session at 9:50 a.m. Eastern Time. Investors can access the live webcast via Seer's website, with an archived replay available post-conference. Seer’s innovative Proteograph Product Suite facilitates deep proteomic analysis efficiently and is designed for laboratory use. This suite is not intended for diagnostic procedures and aims to enhance research capabilities in proteomics.
Seer, Inc. (Nasdaq: SEER) will report its financial results for Q4 and full year 2022 on March 2, 2023, after market close. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET, available via webcast on the Investor section of Seer’s website. Seer specializes in proteomics, offering the Proteograph Product Suite, which enables deep, unbiased proteomic analysis efficiently. This solution uses proprietary engineered nanoparticles and is designed for use in a variety of laboratory settings.
Seer, Inc. (Nasdaq: SEER) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. Management will present at 3:00 p.m. PT / 6:00 p.m. ET, followed by a Q&A session. Investors can access a live webcast on the Investor section of Seer's website, with an archived replay available afterwards.
Seer specializes in proteomics, offering the Proteograph™ Product Suite, a unique solution for deep proteomic analysis. For further details, visit www.seer.bio.